Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageAt Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $151.8MThe company’s own SEC segment disclosure.
- Testing$145.7M96%
- Testing Other$4.5M3%
- Biopharmaceutical And Other Biopharmaceutical$802.0K1%
- Biopharmaceutical And Other$802.0K1%
Veracyte, Inc. (VCYT) reported revenue of $139M in Q1 2026 (quarter ended Mar 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $29M (21% of revenue). For the full year FY2025, revenue was $517M (+16% year on year) and net income $66M. Its largest product in Jun 2026 was Testing at $146M, 96% of the disclosed total, well ahead of Testing Other at 3.0%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #14 of 17 by Smart Score